首页/数据集/Clinical characteristics of 17 patients with stage III thymoma after 12 weeks of treatment.

Clinical characteristics of 17 patients with stage III thymoma after 12 weeks of treatment.

Figshare2016-12-17 更新2026-04-29 收录

数据链接：

https://figshare.com/articles/dataset/Clinical_characteristics_of_17_patients_with_stage_III_thymoma_after_12_weeks_of_treatment_/4477805 数据链接链接失效反馈

官方服务：

资源简介：

Clinical characteristics of 17 patients with stage III thymoma after 12 weeks of treatment.

应用场景：

创建时间：

2016-12-17

转移性结直肠癌治疗

抗肿瘤药物疗效评估

The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).

NIAID Data Ecosystem120

An observational study of apatinib combined with XELOX regimen in postoperative adjuvant therapy of colorectal cancer

结直肠癌辅助化疗

抗肿瘤药物疗效评估

Interventions: experimental group:Apatinib combined with oxaliplatin and capecitabine (XELOX) g Primary outcome(s): Disease free survival Study Design: Single arm

NIAID Data Ecosystem80

热化疗吡柔比星和卡介盖林高危非肌层浸润性膀胱癌患者的 a retrospective study

膀胱癌治疗

抗肿瘤药物疗效评估

T t疗效和安全性胱热内化疗（HIVEC）吡柔比星（THP）卡介盖林（BCG 治疗高危非肌层浸润性膀胱癌（NMIBC）患者的膀

Figshare2023-12-10 更新40

精准诊疗制剂药效学数据（肿瘤模型；疗效/成像/生存；武汉；2020.12-2025.11）

抗肿瘤药物疗效评估

临床前动物模型

数据内容：肿瘤生长/抑瘤率、体重与一般状态、终点组织采样结果；成像数据与定量结果，并配套实验分组、给药方案、时间点、统计分析表与阶段性报告。采集方案：按肿瘤模型建立与给药方案制定采集计划；完整记录动物信息、分组随机化、给药剂量/途径/频次、观察与成像时间点、样本处理流程；

国家基础学科公共科学数据中心100

DMAMCL inhibition of intracranial C6 tumor growth.

抗肿瘤药物疗效评估

脑胶质瘤模型

Note: DMA-25, DMA-50, and DMA-100 represent DMAMCL at doses of 25, 50, and 100 mg/kg, respectively. Inhibition represents the percent decrease in tumor weight compared to the vehicle group. *p < 0.05,

NIAID Data Ecosystem50

Clinical characteristics of 17 patients with stage III thymoma after 12 weeks of treatment.

资源简介：

相关数据集